ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bayer Licenses Trius Antibiotic

by Lisa M. Jarvis
August 1, 2011 | APPEARED IN VOLUME 89, ISSUE 31

Bayer Pharma will pay Trius Therapeutics $25 million up front for regional rights to torezolid, an antibiotic against gram-positive bacteria that is in Phase III trials to treat acute bacterial skin and skin structure infections (ABSSSI). The San Diego-based firm will allow Bayer to develop the antibiotic in Africa, Latin America, the Middle East, and Asia excluding North and South Korea. Bayer will pay 25% of the costs necessary to gain approval for torezolid as a treatment for ABSSSI and pneumonia, and potentially pay up to $69 million more in milestones.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment